Pharmacology and structure of P2Y receptors

Neuropharmacology

Volumn 104, Issue , 2016, Pages 50-61

  Von Kügelgen, Ivar ^a   Hoffmann, Kristina ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Adenine nucleotides; Crystal structure; Inflammation; Neuromodulation; P2Y receptors; Platelet aggregation; Receptor ligands; Uracil nucleotides

Indexed keywords

CANGRELOR; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y11 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y13 RECEPTOR; PURINERGIC P2Y14 RECEPTOR; PURINERGIC P2Y2 RECEPTOR; PURINERGIC P2Y4 RECEPTOR; PURINERGIC P2Y6 RECEPTOR; SURAMIN; TICAGRELOR; UNCLASSIFIED DRUG; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; PURINERGIC P2Y RECEPTOR AGONIST; PURINERGIC P2Y RECEPTOR ANTAGONIST; URIDINE TRIPHOSPHATE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; BINDING SITE; BONE METABOLISM; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; HEART INFARCTION; HUMAN; IMMUNOMODULATION; MICROGLIA; NERVE FIBER GROWTH; NEUROMODULATION; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; ANIMAL; BRAIN; CARDIOVASCULAR DISEASE; CHEMISTRY; DEGENERATIVE DISEASE; METABOLISM; NERVE CELL; PHYSIOLOGY;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANIMALS; BRAIN; CARDIOVASCULAR DISEASES; HUMANS; MICROGLIA; NEURODEGENERATIVE DISEASES; NEURONS; PLATELET AGGREGATION; PURINERGIC P2Y RECEPTOR AGONISTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y; URIDINE TRIPHOSPHATE;

EID: 84955310855     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.10.030     Document Type: Review

References (255)

1. M.P. Abbracchio, G. Burnstock, J.M. Boeynaems, E.A. Barnard, J.L. Boyer, C. Kennedy, and et al. International Union of pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy Pharmacol. Rev. 58 2006 281 341
2. D. Ajit, L.T. Woods, J.M. Camden, C.N. Thebeau, F.G. El-Sayed, G.W. Greeson, L. Erb, M.J. Petris, D.C. Miller, G.Y. Sun, and G.A. Weisman Loss of P2Y2 nucleotide receptors enhances early pathology in the TgCRND8 mouse model of Alzheimer's disease Mol. Neurobiol. 49 2014 1031 1042
3. L. Albizu, M. Cottet, M. Kralikova, S. Stoev, R. Seyer, I. Brabet, and et al. Time-resolved FRET between GPCR ligands reveals oligomers in native tissues Nat. Chem. Biol. 6 2010 587 594
4. I. Algaier, J.A. Jakubowski, F. Asai, and I. von Kügelgen Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor J. Thromb. Haemost. 6 2008 1908 1914
5. F. Alkayed, M. Kashimata, N. Koyama, T. Hayashi, Y. Tamura, and Y. Azuma P2Y11 purinoceptor mediates the ATP-enhanced chemotactic response of rat neutrophils J. Pharmacol. Sci. 120 2012 288 295
6. S. Amadio, C. Parisi, C. Montilli, A.S. Carrubba, S. Apolloni, and C. Volonté P2Y(12) receptor on the verge of a neuroinflammatory breakdown Mediat. Inflamm. 2014 2014 975849
7. S. Amisten, O. Melander, A.K. Wihlborg, G. Berglund, and D. Erlinge Increased risk of acute myocardial infarction and elevated levels of C-reactive protein in carriers of the Thr-87 variant of the ATP receptor P2Y11 Eur. Heart J. 28 2007 13 18
8. P. Andre, S.M. Delaney, T. LaRocca, D. Vincent, F. DeGuzman, M. Jurek, and et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries J. Clin. Invest 112 2003 398 406
9. C.K. Ayata, S.C. Ganal, B. Hockenjos, K. Willim, R.P. Vieira, M. Grimm, and et al. Purinergic P2Y2 receptors promote neutrophil infiltration and hepatocyte death in mice with acute liver injury Gastroenterology 143 2012 1620 1629
10. K. Ayyanathan, T.E. Webb, A.K. Sandhu, R.S. Athwal, E.A. Barnard, and S.P. Kunapuli Cloning and chromosomal localization of the human P2Y1 purinoceptor Biochem. Biophys. Res. Commun. 218 1996 783 788
11. S. Azran, D. Förster, O. Danino, Y. Nadel, G. Reiser, and B. Fischer Highly efficient biocompatible neuroprotectants with dual activity as antioxidants and P2Y receptor agonists J. Med. Chem. 56 2013 4938 4952
12. A. Azroyan, V. Cortez-Retamozo, R. Bouley, R. Liberman, Y.C. Ruan, E. Kiselev, and et al. Renal intercalated cells sense and mediate inflammation via the P2Y14 receptor PLoS One 10 2015 e0121419
13. P. Bach, J. Boström, K. Brickmann, J.J. van Giezen, R.D. Groneberg, D.M. Harvey, and et al. Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor Eur. J. Med. Chem. 65 2013 360 375
14. R. Balasubramanian, B. Robaye, J.M. Boeynaems, and K.A. Jacobson Enhancement of glucose uptake in mouse skeletal muscle cells and adipocytes by P2Y6 receptor agonists PLoS One 9 2014 e116203
15. J.A. Ballesteros, and H. Weinstein Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors P.M. Conn, S.C. Sealfon, Methods in Neurosciences vol. 25 1995 Academic Press USA 366 428
16. Y. Baqi, K. Atzler, M. Köse, M. Glänzel, and C.E. Müller High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors J. Med. Chem. 52 2009 3784 3793
17. P. Barragán-Iglesias, J.B. Pineda-Farias, C. Cervantes-Durán, M. Bravo-Hernández, H.I. Rocha-González, J. Murbartián, and V. Granados-Soto Role of spinal P2Y6 and P2Y11 receptors in neuropathic pain in rats: possible involvement of glial cells Mol. Pain 10 2014 29
18. P. Barragán-Iglesias, L. Mendoza-Garcés, J.B. Pineda-Farias, V. Solano-Olivares, J. Rodríguez-Silverio, F.J. Flores-Murrieta, and et al. Participation of peripheral P2Y1, P2Y6 and P2Y11 receptors in formalin-induced inflammatory pain in rats Pharmacol. Biochem. Behav. 128 2015 23 32
19. M.O. Barrett, J.I. Sesma, C.B. Ball, P.S. Jayasekara, K.A. Jacobson, E.R. Lazarowski, and T.K. Harden A selective high-affinity antagonist of the P2Y14 receptor inhibits UDP-glucose-stimulated chemotaxis of human neutrophils Mol. Pharmacol. 84 2013 41 49
20. A. Ben Addi, D. Cammarata, P.B. Conley, J.M. Boeynaems, and B. Robaye Role of the P2Y12 receptor in the modulation of murine dendritic cell function by ADP J. Immunol. 185 2010 5900 5906
21. P. Besada, D.H. Shin, S. Costanzi, H. Ko, C. Mathé, J. Gagneron, and et al. Structure-activity relationships of uridine 5′-diphosphate analogues at the human P2Y6 receptor J. Med. Chem. 49 2006 5532 5543
22. D. Blom, T.T. Yamin, M.F. Champy, M. Selloum, E. Bedu, E. Carballo-Jane, and et al. Altered lipoprotein metabolism in P2Y(13) knockout mice Biochim. Biophys. Acta 1801 2010 1349 1360
23. E. Boda, F. Viganò, P. Rosa, M. Fumagalli, V. Labat-Gest, F. Tempia, and et al. The GPR17 receptor in NG2 expressing cells: focus on in vivo cell maturation and participation in acute trauma and chronic damage Glia 59 2011 1958 1973
24. E.T. Bodor, G.L. Waldo, S.B. Hooks, J. Corbitt, J.L. Boyer, and T.K. Harden Purification and functional reconstitution of the human P2Y12 receptor Mol. Pharmacol. 64 2003 1210 1216
25. Y.D. Bogdanov, S.S. Wildman, M.P. Clements, B.F. King, and G. Burnstock Molecular cloning and characterization of rat P2Y4 nucleotide receptor Br. J. Pharmacol. 124 1998 428 430
26. J.L. Boyer, I.E. Zohn, K.A. Jacobson, and T.K. Harden Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors Br. J. Pharmacol. 113 1994 614 620
27. J.L. Boyer, A. Mohanram, E. Camaioni, K.A. Jacobson, and T.K. Harden Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2′-deoxyadenosine 3′,5′-bisphosphate Br. J. Pharmacol. 124 1998 1 3
28. J.L. Boyer, M. Adams, R.G. Ravi, K.A. Jacobson, and T.K. Harden 2-Chloro N6-methyl-N-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate is a selective high affinity P2Y1 receptor antagonist Br. J. Pharmacol. 135 2002 2004 2010
29. A. Brunschweiger, and C.E. Müller P2 receptors activated by uracil nucleotides-an update Curr. Med. Chem. 13 2006 289 312
30. G. Burnstock Physiology and pathophysiology of purinergic neurotransmission Physiol. Rev. 87 2007 659 797
31. G. Burnstock, and J.M. Boeynaems Purinergic signalling and immune cells Purinergic Signal 10 2014 529 564
32. G. Burnstock, and C. Kennedy Is there a basis for distinguishing two types of P2-purinoceptor? Gen. Pharmacol. 16 1985 433 440
33. G. Burnstock, U. Krügel, M.P. Abbracchio, and P. Illes Purinergic signalling: from normal behaviour to pathological brain function Prog. Neurobiol. 95 2011 229 274
34. E. Camaioni, J.L. Boyer, A. Mohanram, T.K. Harden, and K.A. Jacobson Deoxyadenosine-bisphosphate derivatives as potent antagonists at P2Y1 receptors J. Med. Chem. 41 1998 183 190
35. R.L. Carter, I.P. Fricks, M.O. Barrett, L.E. Burianek, Y. Zhou, H. Ko, and et al. Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor Mol. Pharmacol. 76 2009 1341 1348
36. M. Cattaneo The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects Blood 117 2011 2102 2112
37. M. Cattaneo, M.L. Zighetti, R. Lombardi, C. Martinez, A. Lecchi, P.B. Conley, and et al. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding Proc. Natl. Acad. Sci. U. S. A. 100 2003 1978 1983
38. M. Cattaneo, A. Lecchi, M. Ohno, B.V. Joshi, P. Besada, S. Tchilibon, and et al. Antiaggregatory activity in human platelets of potent antagonists of the P2Y1 receptor Biochem. Pharmacol. 68 2004 1995 2002
39. S. Chadet, F. Ivanes, L. Benoist, C. Salmon-Gandonnière, R. Guibon, F. Velge-Roussel, and et al. Hypoxia/Reoxygenation inhibits P2Y11 receptor expression and its immunosuppressive activity in human dendritic cells J. Immunol. 195 2015 651 660
40. J.K. Chambers, L.E. Macdonald, H.M. Sarau, R.S. Ames, K. Freeman, J.J. Foley, and et al. A G protein-coupled receptor for UDP-glucose J. Biol. Chem. 275 2000 10767 10771
41. K. Chang, K. Hanaoka, M. Kumada, and Y. Takuwa Molecular cloning and functional analysis of a novel P2 nucleotide receptor J. Biol. Chem. 270 1995 26152 26158
42. S.J. Charlton, C.A. Brown, G.A. Weisman, J.T. Turner, L. Erb, and M.R. Boarder PPADS and suramin as antagonists at cloned P2Y- and P2U-purinoceptors Br. J. Pharmacol. 118 1996 704 710
43. S.J. Charlton, C.A. Brown, G.A. Weisman, J.T. Turner, L. Erb, and M.R. Boarder Cloned and transfected P2Y4 receptors: characterization of a suramin and PPADS-insensitive response to UTP Br. J. Pharmacol. 119 1996 1301 1303
44. M.E. Charlton, A.S. Williams, M. Fogliano, P.M. Sweetnam, and R.S. Duman The isolation and characterization of a novel G protein-coupled receptor regulated by immunologic challenge Brain Res. 764 1997 141 148
45. Z.P. Chen, N. Krull, S. Xu, A. Levy, and S.L. Lightman Molecular cloning and functional characterization of a rat pituitary G protein-coupled adenosine triphosphate (ATP) receptor Endocrinology 137 1996 1833 1840
46. M. Chhatriwala, R.G. Ravi, R.I. Patel, J.L. Boyer, K.A. Jacobson, and T.K. Harden Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog J. Pharmacol. Exp. Ther. 311 2004 1038 1043
47. J. Cho, R. Yusuf, S. Kook, E. Attar, D. Lee, B. Park, and et al. Purinergic P2Y14 receptor modulates stress-induced hematopoietic stem/progenitor cell senescence J. Clin. Invest 124 2014 3159 3171
48. R.C. Choi, J. Simon, K.W. Tsim, and E.A. Barnard Constitutive and agonist-induced dimerizations of the P2Y1 receptor: relationship to internalization and scaffolding J. Biol. Chem. 283 2008 11050 11063
49. S. Cicko, M. Lucattelli, T. Müller, M. Lommatzsch, G. De Cunto, S. Cardini, and et al. Purinergic receptor inhibition prevents the development of smoke-induced lung injury and emphysema J. Immunol. 185 2010 688 697
50. R. Cohen, A. Shainberg, E. Hochhauser, Y. Cheporko, A. Tobar, E. Birk, and et al. UTP reduces infarct size and improves mice heart function after myocardial infarct via P2Y2 receptor Biochem. Pharmacol. 82 2011 1126 1133
51. D. Communi, S. Pirotton, M. Parmentier, and J.M. Boeynaems Cloning and functional expression of a human uridine nucleotide receptor J. Biol. Chem. 270 1995 30849 30852
52. D. Communi, S. Motte, J.M. Boeynaems, and S. Pirotton Pharmacological characterization of the human P2Y4 receptor Eur. J. Pharmacol. 317 1996 383 389
53. D. Communi, M. Parmentier, and J.M. Boeynaems Cloning, functional expression and tissue distribution of the human P2Y6 receptor Biochem. Biophys. Res. Commun. 222 1996 303 308
54. D. Communi, C. Govaerts, M. Parmentier, and J.M. Boeynaems Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase J. Biol. Chem. 272 1997 31969 31973
55. D. Communi, B. Robaye, and J.M. Boeynaems Pharmacological characterization of the human P2Y11 receptor Br. J. Pharmacol. 128 1999 1199 1206
56. D. Communi, N.S. Gonzalez, M. Detheux, S. Brezillon, V. Lannoy, M. Parmentier, and et al. Identification of a novel human ADP receptor coupled to Gi J. Biol. Chem. 276 2001 41479 41485
57. S. Costanzi, T. Santhosh Kumar, R. Balasubramanian, T. Kendall Harden, and K.A. Jacobson Virtual screening leads to the discovery of novel non-nucleotide P2Y1 receptor antagonists Bioorg Med. Chem. 20 2012 5254 5261
58. M. Cöster, D. Wittkopf, A. Kreuchwig, G. Kleinau, D. Thor, G. Krause, and T. Schöneberg Using ortholog sequence data to predict the functional relevance of mutations in G-protein-coupled receptors FASEB J. 26 2012 3273 3281
59. V.L. Cressman, E. Lazarowski, L. Homolya, R.C. Boucher, B.H. Koller, and B.R. Grubb Effect of loss of P2Y2 receptor gene expression on nucleotide regulation of murine epithelial Cl- transport J. Biol. Chem. 274 1999 26461 26468
60. N. D'Ambrosi, M. Lafrate, E. Saba, P. Rosa, and C. Volonté Comparative analysis of P2Y4 and P2Y6 receptor architecture in native and transfected neuronal systems Biochim. Biophys. Acta 1768 2007 1592 1599
61. A. Das, H. Ko, L.E. Burianek, M.O. Barrett, T.K. Harden, and K.A. Jacobson Human P2Y14 receptor agonists: truncation of the hexose moiety of uridine-5′-diphosphoglucose and its replacement with alkyl and aryl groups J. Med. Chem. 53 2010 471 480
62. Z. Ding, Y.S. Bynagari, S.R. Mada, J.A. Jakubowski, and S.P. Kunapuli Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y12 receptor when interacting with antagonists J. Thromb. Haemost. 7 2009 232 234
63. J.A. Dranoff, A.F. O'Neill, A.M. Franco, S.Y. Cai, G.C. Connolly, N. Ballatori, and et al. A primitive ATP receptor from the little skate Raja erinacea J. Biol. Chem. 275 2000 30701 30706
64. D. Ecke, M.E. Tulapurkar, V. Nahum, B. Fischer, and G. Reiser Opposite diastereoselective activation of P2Y1 and P2Y11 nucleotide receptors by adenosine 5′-O-(alpha-boranotriphosphate) analogues Br. J. Pharmacol. 149 2006 416 423
65. D. Ecke, T. Hanck, M.E. Tulapurkar, R. Schäfer, M. Kassack, R. Stricker, and et al. Hetero-oligomerization of the P2Y11 receptor with the P2Y1 receptor controls the internalization and ligand selectivity of the P2Y11 receptor Biochem. J. 409 2008 107 116
66. F.G. El-Sayed, J.M. Camden, L.T. Woods, M.G. Khalafalla, M.J. Petris, L. Erb, and G.A. Weisman P2Y2 nucleotide receptor activation enhances the aggregation and self-organization of dispersed salivary epithelial cells Am. J. Physiol. Cell Physiol. 307 2014 C83 C96
67. A. El-Tayeb, K.J. Griessmeier, and C.E. Müller Synthesis and preliminary evaluation of [3H]PSB-0413, a selective antagonist radioligand for platelet P2Y12 receptors Bioorg Med. Chem. Lett. 15 2005 5450 5452
68. A. El-Tayeb, A. Qi, and C.E. Müller Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors J. Med. Chem. 49 2006 7076 7087
69. A. El-Tayeb, A. Qi, R.A. Nicholas, and C.E. Müller Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors J. Med. Chem. 54 2011 2878 2890
70. L. Erb, C. Cao, D. Ajit, and G.A. Weisman P2Y receptors in Alzheimer's disease Biol. Cell 107 2015 1 21
71. J.E. Fabre, M. Nguyen, A. Latour, J.A. Keifer, L.P. Audoly, T.M. Coffman, and et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice Nat. Med. 5 1999 1199 1202
72. A.C. Fabre, C. Malaval, A. Ben Addi, C. Verdier, V. Pons, N. Serhan, L. Lichtenstein, G. Combes, T. Huby, F. Briand, X. Collet, N. Nijstad, U.J. Tietge, B. Robaye, B. Perret, J.M. Boeynaems, and L.O. Martinez P2Y13 receptor is critical for reverse cholesterol transport Hepatology 52 2010 1477 1483
73. A.K. Filippov, J. Simon, E.A. Barnard, and D.A. Brown Coupling of the nucleotide P2Y4 receptor to neuronal ion channels Br. J. Pharmacol. 138 2003 400 406
74. C.J. Foster, D.M. Prosser, J.M. Agans, Y. Zhai, M.D. Smith, J.E. Lachowicz, and et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs J. Clin. Invest 107 2001 1591 1598
75. H. Franke, and P. Illes Nucleotide signaling in astrogliosis Neurosci. Lett. 565 2014 14 22
76. R. Fredriksson, M.C. Lagerström, L.G. Lundin, and H.B. Schioth The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints Mol. Pharmacol. 63 2003 1256 1272
77. K. Freeman, P. Tsui, D. Moore, P.C. Emson, L. Vawter, S. Naheed, and et al. Cloning, pharmacology, and tissue distribution of G-protein-coupled receptor GPR105 (KIAA0001) rodent orthologs Genomics 78 2001 124 128
78. I.P. Fricks, S. Maddileti, R.L. Carter, E.R. Lazarowski, R.A. Nicholas, K.A. Jacobson, and et al. UDP is a competitive antagonist at the human P2Y14 receptor J. Pharmacol. Exp. Ther. 325 2008 588 594
79. I.P. Fricks, R.L. Carter, E.R. Lazarowski, and T.K. Harden Gi-dependent cell signaling responses of the human P2Y14 receptor in model cell systems J. Pharmacol. Exp. Ther. 330 2009 162 168
80. M. Fumagalli, L. Trincavelli, D. Lecca, C. Martini, P. Ciana, and M.P. Abbracchio Cloning, pharmacological characterisation and distribution of the rat G-protein-coupled P2Y13 receptor Biochem. Pharmacol. 68 2004 113 124
81. M. Fumagalli, S. Daniele, D. Lecca, P.R. Lee, C. Parravicini, R.D. Fields, and et al. Phenotypic changes, signaling pathway, and functional correlates of GPR17-expressing neural precursor cells during oligodendrocyte differentiation J. Biol. Chem. 286 2011 10593 10604
82. C. Gachet Regulation of platelet functions by P2 receptors Ann. Rev. Pharmacol. Toxicol. 46 2006 277 300
83. D. Gallego, V. Gil, M. Martínez-Cutillas, N. Mañé, M.T. Martín, and M. Jiménez Purinergic neuromuscular transmission is absent in the colon of P2Y(1) knocked out mice J. Physiol. 590 2012 1943 1956
84. Z.G. Gao, L. Mamedova, S. Tchilibon, A.S. Gross, and K.A. Jacobson 2,2′-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding Biochem. Pharmacol. 68 2004 231 237
85. Z.G. Gao, Y. Ding, and K.A. Jacobson P2Y(13) receptor is responsible for ADP-mediated degranulation in RBL-2H3 rat mast cells Pharmacol. Res. 62 2010 500 505
86. Z.G. Gao, Q. Wei, M.P. Jayasekara, and K.A. Jacobson The role of P2Y(14) and other P2Y receptors in degranulation of human LAD2 mast cells Purinergic Signal 9 2013 31 40
87. R.A. Garcia, M. Yan, D. Search, R. Zhang, N.L. Carson, C.S. Ryan, and et al. P2Y6 receptor potentiates pro-inflammatory responses in macrophages and exhibits differential roles in atherosclerotic lesion development PLoS One 9 2014 e111385
88. J.Y. Gauthier, M. Belley, D. Deschênes, J.F. Fournier, S. Gagné, Y. Gareau, and et al. The identification of 4,7-disubstituted naphthoic acid derivatives as UDP-competitive antagonists of P2Y14 Bioorg Med. Chem. Lett. 21 2011 2836 2839
89. E. Ghanem, B. Robaye, T. Leal, J. Leipziger, W. Van Driessche, R. Beauwens, and et al. The role of epithelial P2Y2 and P2Y4 receptors in the regulation of intestinal chloride secretion Br. J. Pharmacol. 146 2005 364 369
90. G. Giannattasio, S. Ohta, J.R. Boyce, W. Xing, B. Balestrieri, and J.A. Boyce The purinergic G protein-coupled receptor 6 inhibits effector T cell activation in allergic pulmonary inflammation J. Immunol. 187 2011 1486 1495
91. T. Ginsburg-Shmuel, M. Haas, M. Schumann, G. Reiser, O. Kalid, N. Stern, and et al. 5-OMe-UDP is a potent and selective P2Y6-receptor agonist J. Med. Chem. 53 2010 1673 1685
92. T. Ginsburg-Shmuel, M. Haas, D. Grbic, G. Arguin, Y. Nadel, F.P. Gendron, and et al. UDP made a highly promising stable, potent, and selective P2Y6-receptor agonist upon introduction of a boranophosphate moiety Bioorg Med. Chem. 20 2012 5483 5495
93. A. Grosche, T. Pannicke, J. Chen, P. Wiedemann, A. Reichenbach, and A. Bringmann Disruption of endogenous purinergic signaling inhibits vascular endothelial growth factor- and glutamate-induced osmotic volume regulation of Müller glial cells in knockout mice Ophthalmic Res. 50 2013 209 214
94. D. Guay, C. Beaulieu, M. Belley, S.N. Crane, J. DeLuca, Y. Gareau, and et al. Synthesis and SAR of pyrimidine-based, non-nucleotide P2Y14 receptor antagonists Bioorg Med. Chem. Lett. 21 2011 2832 2835
95. D. Guo, I. von Kügelgen, S. Moro, Y.C. Kim, and K.A. Jacobson Evidence for the recognition of non-nucleotide antagonists within the transmembrane domains of the human P2Y1 receptor Drug Devel Res. 57 2002 173 181
96. S.J. Guzman, H. Schmidt, H. Franke, U. Krügel, J. Eilers, P. Illes, and Z. Gerevich P2Y1 receptors inhibit long-term depression in the prefrontal cortex Neuropharmacology 59 2010 406 415
97. M. Haas, A. Shaaban, and G. Reiser Alanine-(87)-threonine polymorphism impairs signaling and internalization of the human P2Y11 receptor, when co-expressed with the P2Y1 receptor J. Neurochem. 129 2014 602 613
98. T.K. Harden, J.I. Sesma, I.P. Fricks, and E.R. Lazarowski Signalling and pharmacological properties of the P2Y14 receptor Acta Physiol. (Oxf) 199 2010 149 160
99. M. Hashimoto, A. Sugidachi, T. Isobe, Y. Niitsu, T. Ogawa, J.A. Jakubowski, and et al. The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: evidence for specific inhibition of P2Y12 receptors by prasugrel Biochem. Pharmacol. 74 2007 1003 1009
100. S.E. Haynes, G. Hollopeter, G. Yang, D. Kurpius, M.E. Dailey, W.B. Gan, and et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides Nat. Neurosci. 9 2006 1512 1519
101. B. Hechler, C. Nonne, E.J. Roh, M. Cattaneo, J.P. Cazenave, F. Lanza, and et al. MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice J. Pharmacol. Exp. Ther. 31 2006 556 563
102. C. Heine, K. Sygnecka, N. Scherf, M. Grohmann, A. Bräsigk, and H. Franke P2Y(1) receptor mediated neuronal fibre outgrowth in organotypic brain slice co-cultures Neuropharmacology 93 2015 252 266
103. D.J. Henderson, D.G. Elliot, G.M. Smith, T.E. Webb, and I.A. Dainty Cloning and characterisation of a bovine P2Y receptor Biochem. Biophys. Res. Commun. 212 1995 648 656
104. S. Hennen, H. Wang, L. Peters, N. Merten, K. Simon, A. Spinrath, and et al. Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist Sci. Signal 6 2013 ra93
105. J.M. Herbert, A. Tissinier, G. Defreyn, and J.P. Maffrand Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits Arterioscler. Thromb. 13 1993 1171 1179
106. C.L. Herold, A.D. Qi, T.K. Harden, and R.A. Nicholas Agonist versus antagonist action of ATP at the P2Y4 receptor is determined by the second extracellular loop J. Biol. Chem. 279 2004 11456 11464
107. P. Hillmann, G.Y. Ko, A. Spinrath, A. Raulf, I. von Kügelgen, S.C. Wolff, and et al. Key determinants of nucleotide-activated G protein-coupled P2Y2 receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling J. Med. Chem. 52 2009 2762 2775
108. C. Hoffmann, S. Moro, R.A. Nicholas, T.K. Harden, and K.A. Jacobson The role of amino acids in extracellular loops of the human P2Y1 receptor in surface expression and activation processes J. Biol. Chem. 274 1999 14639 14647
109. K. Hoffmann, U. Sixel, F. Di Pasquale, and I. von Kügelgen Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y12-receptor Biochem. Pharmacol. 76 2008 1201 1213
110. K. Hoffmann, Y. Baqi, M.S. Morena, M. Glänzel, C.E. Müller, and I. von Kügelgen Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor J. Pharmacol. Exp. Ther. 331 2009 648 655
111. K. Hoffmann, D.A. Lutz, J. Straßburger, Y. Baqi, C.E. Müller, and I. von Kügelgen Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor J. Thromb. Haemost. 12 2014 1898 1905
112. C. Högberg, O. Gidlöf, F. Deflorian, K.A. Jacobson, A. Abdelrahman, C.E. Müller, and et al. Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y12 receptor-mediated platelet aggregation Thromb. Haemost. 108 2012 119 132
113. G. Hollopeter, H.M. Jantzen, D. Vincent, G. Li, L. England, V. Ramakrishnan, and et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs Nature 409 2001 202 207
114. M. Horckmans, E. Léon-Gómez, B. Robaye, J.L. Balligand, J.M. Boeynaems, C. Dessy, and D. Communi Gene deletion of P2Y4 receptor lowers exercise capacity and reduces myocardial hypertrophy with swimming exercise Am. J. Physiol. Heart Circ. Physiol. 303 2012 H835 H843
115. M. Horckmans, B. Robaye, E. Léon-Gomez, N. Lantz, P. Unger, F. Dol-Gleizes, and et al. P2Y(4) nucleotide receptor: a novel actor in post-natal cardiac development Angiogenesis 15 2012 349 360
116. M. Horckmans, H. Esfahani, C. Beauloye, S. Clouet, L. di Pietrantonio, B. Robaye, and et al. Loss of mouse P2Y4 nucleotide receptor protects against myocardial infarction through endothelin-1 downregulation J. Immunol. 194 2015 1874 1881
117. G. Horváth, F. Gölöncsér, C. Csölle, K. Király, R.D. Andó, M. Baranyi, and et al. Central P2Y12 receptor blockade alleviates inflammatory and neuropathic pain and cytokine production in rodents Neurobiol. Dis. 70 2014 162 178
118. M. Hou, T.K. Harden, C.M. Kuhn, B. Baldetorp, E. Lazarowski, W. Pendergast, and et al. UDP acts as a growth factor for vascular smooth muscle cells by activation of P2Y6 receptors Am. J. Physiol. Heart Circ. Physiol. 282 2002 H784 H792
119. D. Houston, M. Ohno, R.A. Nicholas, K.A. Jacobson, and T.K. Harden [32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors Br. J. Pharmacol. 147 2006 459 467
120. M. Idzko, D. Ferrari, and H.K. Eltzschig Nucleotide signalling during inflammation Nature 509 2014 310 317
121. A.H. Ingall, J. Dixon, A. Bailey, M.E. Coombs, D. Cox, J.I. McInally, and et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy J. Med. Chem. 42 1999 213 220
122. A.A. Ivanov, H. Ko, L. Cosyn, S. Maddileti, P. Besada, I. Fricks, and et al. Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate J. Med. Chem. 50 2007 1166 1176
123. P.F. Jacob, S.H. Vaz, J.A. Ribeiro, and A.M. Sebastião P2Y1 receptor inhibits GABA transport through a calcium signalling-dependent mechanism in rat cortical astrocytes Glia 62 2014 1211 1226
124. K.A. Jacobson, Z.G. Gao, S. Paoletta, E. Kiselev, S. Chakraborty, P.S. Jayasekara, and et al. John Daly lecture: structure-guided drug design for adenosine and P2Y receptors Comput. Struct. Biotechnol. J. 13 2014 286 298
125. S. James, A. Akerblom, C.P. Cannon, H. Emanuelsson, S. Husted, H. Katus, and et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient outcomes (PLATO) trial Am. Heart J. 157 2009 599 605
126. R. Janssens, D. Communi, S. Pirotton, M. Samson, M. Parmentier, and J.M. Boeynaems Cloning and tissue distribution of the human P2Y1 receptor Biochem. Biophys. Res. Commun. 221 1996 588 593
127. P.S. Jayasekara, M.O. Barrett, C.B. Ball, K.A. Brown, E. Hammes, R. Balasubramanian, and et al. 4-Alkyloxyimino derivatives of uridine-5'-triphosphate: distal modification of potent agonists as a strategy for molecular probes of P2Y2, P2Y4, and P2Y6 receptors J. Med. Chem. 57 2014 3874 3883
128. N.R. Jorgensen, E.L. Grove, P. Schwarz, and P. Vestergaard Clopidogrel and the risk of osteoporotic fractures: a nationwide cohort study J. Intern Med. 272 2012 385 393
129. G. Kauffenstein, B. Hechler, J.P. Cazenave, and C. Gachet Adenine triphosphate nucleotides are antagonists at the P2Y12 receptor J. Thromb. Haemost. 2 2004 1980 1988
130. C. Kennedy, A.D. Qi, C.L. Herold, T.K. Harden, and R.A. Nicholas ATP, an agonist at the rat P2Y4 receptor, is an antagonist at the human P2Y4 receptor Mol. Pharmacol. 57 2000 926 931
131. H.S. Kim, M. Ohno, B. Xu, H.O. Kim, Y. Choi, X.D. Ji, and et al. 2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists J. Med. Chem. 46 2003 4974 4987
132. Y.C. Kim, J.S. Lee, K. Sak, F. Marteau, L. Mamedova, J.M. Boeynaems, and et al. Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor Biochem. Pharmacol. 70 2005 266 274
133. H.J. Kim, D. Ajit, T.S. Peterson, Y. Wang, J.M. Camden, W. Gibson Wood, and et al. Nucleotides released from Aβ1-42 -treated microglial cells increase cell migration and Aβ1-42 uptake through P2Y2 receptor activation J. Neurochem. 121 2012 228 238
134. M. Kinoshita, K. Nasu-Tada, K. Fujishita, K. Sato, and S. Koizumi Secretion of matrix metalloproteinase-9 from astrocytes by inhibition of tonic P2Y14-receptor-mediated signal(s) Cell Mol. Neurobiol. 33 2013 47 58
135. E. Kiselev, M.O. Barrett, V. Katritch, S. Paoletta, C.D. Weitzer, K.A. Brown, and et al. Exploring a 2-naphthoic acid template for the structure-based design of P2Y14 receptor antagonist molecular probes ACS Chem. Biol. 9 2014 2833 2842
136. H. Ko, I. Fricks, A.A. Ivanov, T.K. Harden, and K.A. Jacobson Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor J. Med. Chem. 50 2007 2030 2039
137. H. Ko, R.L. Carter, L. Cosyn, R. Petrelli, S. de Castro, P. Besada, and et al. Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists Bioorg Med. Chem. 16 2008 6319 6332
138. S. Koizumi, Y. Shigemoto-Mogami, K. Nasu-Tada, Y. Shinozaki, K. Ohsawa, M. Tsuda, B.V. Joshi, K.A. Jacobson, S. Kohsaka, and K. Inoue UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis Nature 446 2007 1091 1095
139. S. Koizumi, K. Ohsawa, K. Inoue, and S. Kohsaka Purinergic receptors in microglia: functional modal shifts of microglia mediated by P2 and P1 receptors Glia 61 2013 47 54
140. J. Korcok, L.N. Raimundo, X. Du, S.M. Sims, and S.J. Dixon P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts J. Biol. Chem. 280 2005 16909 16915
141. B.R. Kornum, M. Kawashima, J. Faraco, L. Lin, T.J. Rico, S. Hesselson, and et al. Common variants in P2RY11 are associated with narcolepsy Nat. Genet. 43 2011 66 71
142. U. Krügel, L. Köles, and P. Illés Integration of neuronal and glial signalling by pyramidal cells of the rat prefrontal cortex; control of cognitive functions and addictive behaviour by purinergic mechanisms Neuropsychopharmacol. Hung 15 2013 206 213
143. M.C. Lagerström, and H.B. Schiöth Structural diversity of G protein-coupled receptors and significance for drug discovery Nat. Rev. Drug Discov. 7 2008 339 357
144. M.A. Laplante, L. Monassier, M. Freund, P. Bousquet, and C. Gachet The purinergic P2Y1 receptor supports leptin secretion in adipose tissue Endocrinology 151 2010 2060 2070
145. E.R. Lazarowski, W.C. Watt, M.J. Stutts, R.C. Boucher, and T.K. Harden Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate Br. J. Pharmacol. 116 1995 1619 1627
146. E.R. Lazarowski, L.G. Rochelle, W.K. O'Neal, C.M. Ribeiro, B.R. Grubb, V. Zhang, and et al. Cloning and functional characterization of two murine uridine nucleotide receptors reveal a potential target for correcting ion transport deficiency in cystic fibrosis gallbladder J. Pharmacol. Exp. Ther. 297 2001 43 49
147. A. Lecchi, C. Razzari, S. Paoletta, A. Dupuis, L. Nakamura, P. Ohlmann, and et al. Identification of a new dysfunctional platelet P2Y12 receptor variant associated with bleeding diathesis Blood 125 2015 1006 1013
148. J. Leipziger Control of epithelial transport via luminal P2 receptors Am. J. Physiol. Ren. Physiol. 284 2003 F419 F432
149. C. Léon, C. Vial, J.P. Cazenave, and C. Gachet Cloning and sequencing of a human cDNA encoding endothelial P2Y1 purinoceptor Gene 171 1996 295 297
150. C. Léon, B. Hechler, C. Vial, C. Leray, J.P. Cazenave, and C. Gachet The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells FEBS Lett. 403 1997 26 30
151. C. Léon, B. Hechler, M. Freund, A. Eckly, C. Vial, P. Ohlmann, and et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y1 receptor-null mice J. Clin. Invest 104 1999 1731 1737
152. Q. Li, M. Olesky, R.K. Palmer, T.K. Harden, and R.A. Nicholas Evidence that the p2y3 receptor is the avian homologue of the mammalian P2Y6 receptor Mol. Pharmacol. 54 1998 541 546
153. L. Lichtenstein, N. Serhan, S. Espinosa-Delgado, A. Fabre, W. Annema, U.J. Tietge, and et al. Increased atherosclerosis in P2Y13/apolipoprotein E double-knockout mice: contribution of P2Y13 to reverse cholesterol transport Cardiovasc Res. 106 2015 314 323
154. E. Liverani, M.C. Rico, L. Yaratha, A.Y. Tsygankov, L.E. Kilpatrick, and S.P. Kunapuli LPS-induced systemic inflammation is more severe in P2Y12 null mice J. Leukoc. Biol. 95 2014 313 323
155. E. Liverani, L.E. Kilpatrick, A.Y. Tsygankov, and S.P. Kunapuli The role of P2Y12 receptor and activated platelets during inflammation Curr. Drug Targets 15 2014 720 728
156. K.D. Lustig, A.K. Shiau, A.J. Brake, and D. Julius Expression cloning of an ATP receptor from mouse neuroblastoma cells Proc. Natl. Acad. Sci. U. S. A. 90 1993 5113 5117
157. J.P. Maffrand, A. Bernat, D. Delebassee, G. Defreyn, J.P. Cazenave, and J.L. Gordon ADP plays a key role in thrombogenesis in rats Thromb. Haemost. 59 1988 225 230
158. S.A. Malin, and D.C. Molliver Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior Mol. Pain 6 2010 21
159. M. Malmsjö, M. Hou, W. Pendergast, D. Erlinge, and L. Edvinsson Potent P2Y6 receptor mediated contractions in human cerebral arteries BMC Pharmacol. 3 2003 4
160. L.K. Mamedova, B.V. Joshi, Z.G. Gao, I. von Kügelgen, and K.A. Jacobson Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors Biochem. Pharmacol. 67 2004 1763 1770
161. F. Marteau, E. Le Poul, D. Communi, D. Communi, C. Labouret, P. Savi, and et al. Pharmacological characterization of the human P2Y13 receptor Mol. Pharmacol. 64 2003 104 112
162. H. Maruoka, M.P. Jayasekara, M.O. Barrett, D.A. Franklin, S. de Castro, N. Kim, and et al. Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate δ-ester modifications as selective agonists of the P2Y(4) receptor J. Med. Chem. 54 2011 4018 4033
163. S. Meis, A. Hamacher, D. Hongwiset, C. Marzian, M. Wiese, N. Eckstein, and et al. NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells J. Pharmacol. Exp. Ther. 332 2010 238 247
164. J. Meister, D. Le Duc, A. Ricken, R. Burkhardt, J. Thiery, H. Pfannkuche, and et al. The G protein-coupled receptor P2Y14 influences insulin release and smooth muscle function in mice J. Biol. Chem. 289 2014 23353 23366
165. E.A. Mellor, A. Maekawa, K.F. Austen, and J.A. Boyce Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells Proc. Natl. Acad. Sci. U. S. A. 98 2001 7964 7969
166. E.A. Mellor, N. Frank, D. Soler, M.R. Hodge, J.M. Lora, K.F. Austen, and J.A. Boyce Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: functional distinction from CysLT1R Proc. Natl. Acad. Sci. U. S. A. 100 2003 11589 11593
167. D. Meltzer, O. Ethan, G. Arguin, Y. Nadel, O. Danino, J. Lecka, J. Sévigny, F.P. Gendron, and B. Fischer Synthesis and structure-activity relationship of uracil nucleotide derivatives towards the identification of human P2Y6 receptor antagonists Bioorg Med. Chem. 23 2015 5764 5773
168. G. Milligan G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function Br. J. Pharmacol. 158 2009 5 14
169. C. Mitchell, N.I. Syed, A. Tengah, A.M. Gurney, and C. Kennedy Identification of contractile P2Y1, P2Y6, and P2Y12 receptors in rat intrapulmonary artery using selective ligands J. Pharmacol. Exp. Ther. 343 2012 755 762
170. V. Morente, R. Pérez-Sen, F. Ortega, J. Huerta-Cepas, E.G. Delicado, and M.T. Miras-Portugal Neuroprotection elicited by P2Y13 receptors against genotoxic stress by inducing DUSP2 expression and MAPK signaling recovery Biochim. Biophys. Acta 1843 2014 1886 1898
171. I. Moreschi, S. Bruzzone, R.A. Nicholas, F. Fruscione, L. Sturla, F. Benvenuto, and et al. Extracellular NAD+ is an agonist of the human P2Y11 purinergic receptor in human granulocytes J. Biol. Chem. 281 2006 31419 31429
172. I. Moreschi, S. Bruzzone, N. Bodrato, C. Usai, L. Guida, R.A. Nicholas, and et al. NAADP+ is an agonist of the human P2Y11 purinergic receptor Cell Calcium 43 2008 344 355
173. S. Moro, D. Guo, E. Camaioni, J.L. Boyer, T.K. Harden, and K.A. Jacobson Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites J. Med. Chem. 41 1998 1456 1466
174. G.B. Morrow, R.A. Nicholas, and C. Kennedy UTP is not a biased agonist at human P2Y(11) receptors Purinergic Signal 10 2014 581 585
175. C.E. Müller P2-pyrimidinergic receptors and their ligands Curr. Pharm. Des. 8 2002 2353 2369
176. T. Müller, B. Robaye, R.P. Vieira, D. Ferrari, M. Grimm, T. Jakob, and et al. The purinergic receptor P2Y2 receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation Allergy 65 2010 1545 1553
177. E. Nandanan, S.Y. Jang, S. Moro, H.O. Kim, M.A. Siddiqui, P. Russ, and et al. Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y1 receptor ligands J. Med. Chem. 43 2000 829 842
178. T. Nguyen, L. Erb, G.A. Weisman, A. Marchese, H.H. Heng, R.C. Garrad, and et al. Cloning, expression, and chromosomal localization of the human uridine nucleotide receptor gene J. Biol. Chem. 270 1995 30845 30848
179. R.A. Nicholas, W.C. Watt, E.R. Lazarowski, Q. Li, and K. Harden Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor Mol. Pharmacol. 50 1996 224 229
180. Y. Niitsu, J.A. Jakubowski, A. Sugidachi, and F. Asai Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity Semin. Thromb. Hemost. 31 2005 184 194
181. S.M. O'Grady, E. Elmquist, T.M. Filtz, R.A. Nicholas, and T.K. Harden A guanine nucleotide-independent inwardly rectifying cation permeability is associated with P2Y1 receptor expression in Xenopus oocytes J. Biol. Chem. 271 1996 29080 29087
182. P. Ohlmann, S. de Castro, G.G. Brown, C. Gachet, K.A. Jacobson, and T.K. Harden Quantification of recombinant and platelet P2Y1 receptors utilizing a [125I]-labeled high-affinity antagonist 2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([125I]MRS2500) Pharmacol. Res. 62 2010 344 351
183. P. Ohlmann, A. Lecchi, A. El-Tayeb, C.E. Müller, M. Cattaneo, and C. Gachet The platelet P2Y(12) receptor under normal and pathological conditions. Assessment with the radiolabeled selective antagonist [(3)H]PSB-0413 Purinergic Signal 9 2013 59 66
184. K. Ohsawa, Y. Irino, T. Sanagi, Y. Nakamura, E. Suzuki, K. Inoue, and S. Kohsaka P2Y12 receptor-mediated integrin-beta1 activation regulates microglial process extension induced by ATP Glia 58 2010 790 801
185. I. Orriss, S. Syberg, N. Wang, B. Robaye, A. Gartland, N. Jorgensen, and et al. Bone phenotypes of P2 receptor knockout mice Front. Biosci. 3 2011 1038 1046
186. I.R. Orriss, N. Wang, G. Burnstock, T.R. Arnett, A. Gartland, B. Robaye, and J.M. Boeynaems The P2Y(6) receptor stimulates bone resorption by osteoclasts Endocrinology 152 2011 3706 3716
187. F. Ortega, R. Pérez-Sen, E.G. Delicado, and M. Teresa Miras-Portugal ERK1/2 activation is involved in the neuroprotective action of P2Y13 and P2X7 receptors against glutamate excitotoxicity in cerebellar granule neurons Neuropharmacology 61 2011 1210 1221
188. R.K. Palmer, J.L. Boyer, J.B. Schachter, R.A. Nicholas, and T.K. Harden Agonist action of adenosine triphosphates at the human P2Y1 receptor Mol. Pharmacol. 54 1998 1118 1123
189. S. Paoletta, D. Sabbadin, I. von Kügelgen, S. Hinz, V. Katritch, K. Hoffmann, and et al. Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information J. Comput. Aided Mol. Des. 29 2015 737 756
190. C.E. Parr, D.M. Sullivan, A.M. Paradiso, E.R. Lazarowski, L.H. Burch, J.C. Olsen, and et al. Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy Proc. Natl. Acad. Sci. U. S. A. 91 1994 3275 3279
191. S.M. Pasternack, I. von Kügelgen, K.A. Aboud, Y.A. Lee, F. Rüschendorf, K. Voss, and et al. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth Nat. Genet. 40 2008 329 334
192. K. Patel, A. Barnes, J. Camacho, C. Paterson, R. Boughtflower, D. Cousens, and et al. Activity of diadenosine polyphosphates at P2Y receptors stably expressed in 1321N1 cells Eur. J. Pharmacol. 430 2001 203 210
193. Y.M. Patel, M. Lordkipanidzé, G.C. Lowe, S.P. Nisar, K. Garner, J. Stockley, and et al. A novel mutation in the P2Y12 receptor and a function-reducing polymorphism in protease-activated receptor 1 in a patient with chronic bleeding J. Thromb. Haemost. 12 2014 716 725
194. W. Pendergast, B.R. Yerxa, J.G. Douglass, S.R. Shaver, R.W. Dougherty, C.C. Redick, and et al. Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates Bioorg Med. Chem. Lett. 11 2001 157 160
195. R. Pérez-Sen, M.J. Queipo, V. Morente, F. Ortega, E.G. Delicado, and M.T. Miras-Portugal Neuroprotection mediated by P2Y13 nucleotide receptors in neurons Comput. Struct. Biotechnol. J. 13 2015 160 168
196. S.A. Potthoff, J. Stegbauer, J. Becker, P.J. Wagenhaeuser, B. Duvnjak, L.C. Rump, and O. Vonend P2Y2 receptor deficiency aggravates chronic kidney disease progression Front. Physiol. 4 2013 234
197. A.D. Qi, C. Kennedy, T.K. Harden, and R.A. Nicholas Differential coupling of the human P2Y11 receptor to phospholipase C and adenylyl cyclase Br. J. Pharmacol. 132 2001 318 326
198. A.D. Qi, A.C. Zambon, P.A. Insel, and R.A. Nicholas An arginine/glutamine difference at the juxtaposition of transmembrane domain 6 and the third extracellular loop contributes to the markedly different nucleotide selectivities of human and canine P2Y11 receptors Mol. Pharmacol. 60 2001 1375 1382
199. A.D. Qi, T.K. Harden, and R.A. Nicholas Is GPR17 a P2Y/leukotriene receptor? Examination of uracil nucleotides, nucleotide sugars, and cysteinyl leukotrienes as agonists of GPR17 J. Pharmacol. Exp. Ther. 347 2013 38 46
200. C. Quintas, D. Pinho, C. Pereira, L. Saraiva, J. Gonçalves, and G. Queiroz Microglia P2Y6 receptors mediate nitric oxide release and astrocyte apoptosis J. Neuroinflammation 11 2014 141
201. V. Ralevic, and G. Burnstock Receptors for purines and pyrimidines Pharmacol. Rev. 50 1998 413 492
202. V. Ralevic, and G. Burnstock Involvement of purinergic signaling in cardiovascular diseases Drug News Perspect. 16 2003 133 140
203. S.G. Rasmussen, H.J. Choi, D.M. Rosenbaum, T.S. Kobilka, F.S. Thian, P.C. Edwards, and et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor Nature 450 2007 383 387
204. L.J. Relvas, M. Makhoul, R. Dewispelaere, L. Caspers, D. Communi, J.M. Boeynaems, and et al. P2Y2R deficiency attenuates experimental autoimmune uveitis development PLoS One 10 2015 e0116518
205. W.R. Rice, F.M. Burton, and D.T. Fiedeldey Cloning and expression of the alveolar type II cell P2u-purinergic receptor Am. J. Respir. Cell Mol. Biol. 12 1995 27 32
206. T. Rieg, M. Gerasimova, J.L. Boyer, P.A. Insel, and V. Vallon P2Y2 receptor activation decreases blood pressure and increases renal Na excretion Am. J. Physiol. Regul. Integr. Comp. Physiol. 301 2011 R510 R518
207. B. Robaye, E. Ghanem, F. Wilkin, D. Fokan, W. Van Driessche, S. Schurmans, and et al. Loss of nucleotide regulation of epithelial chloride transport in the jejunum of P2Y4-null mice Mol. Pharmacol. 63 2003 777 783
208. J. Robichaud, J.F. Fournier, S. Gagné, J.Y. Gauthier, M. Hamel, Y. Han, and et al. Applying the pro-drug approach to afford highly bioavailable antagonists of P2Y(14) Bioorg. Med. Chem. Lett. 21 2011 4366 4368
209. P. Savi, C. Labouret, N. Delesque, F. Guette, J. Lupker, and J.M. Herbert P2Y12, a new platelet ADP receptor, target of clopidogrel Biochem. Biophys. Res. Commun. 283 2001 379 383
210. P. Savi, J.L. Zachayus, N. Delesque-Touchard, C. Labouret, C. Hervé, M.F. Uzabiaga, and et al. The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts Proc. Natl. Acad. Sci. U. S. A. 103 2006 11069 11074
211. P. Schmidt, L. Ritscher, E.N. Dong, T. Hermsdorf, M. Cöster, D. Wittkopf, and et al. Identification of determinants required for agonistic and inverse agonistic ligand properties at the ADP receptor P2Y12 Mol. Pharmacol. 83 2013 256 266
212. J.I. Sesma, S.M. Kreda, N. Steinckwich-Besancon, H. Dang, R. García-Mata, T.K. Harden, and E.R. Lazarowski The UDP-sugar-sensing P2Y(14) receptor promotes rho-mediated signaling and chemotaxis in human neutrophils Am. J. Physiol. Cell Physiol. 303 2012 C490 C498
213. S.R. Shaver, J.L. Rideout, W. Pendergast, J.G. Douglass, E.G. Brown, J.L. Boyer, and et al. Structure-activity relationships of dinucleotides: potent and selective agonists of P2Y receptors Purinergic Signal 1 2005 183 191
214. X. Song, W. Guo, Q. Yu, X. Liu, Z. Xiang, C. He, and G. Burnstock Regional expression of P2Y(4) receptors in the rat central nervous system Purinergic Signal 7 2011 469 488
215. B. Springthorpe, A. Bailey, P. Barton, T.N. Birkinshaw, R.V. Bonnert, R.C. Brown, and et al. From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis Bioorg. Med. Chem. Lett. 17 2007 6013 6018
216. X. Su, D.H. Floyd, A. Hughes, J. Xiang, J.G. Schneider, O. Uluckan, and et al. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling J. Clin. Invest. 122 2012 3579 3592
217. N. Suarez-Huerta, V. Pouillon, J. Boeynaems, and B. Robaye Molecular cloning and characterization of the mouse P2Y4 nucleotide receptor Eur. J. Pharmacol. 416 2001 197 202
218. A. Sugidachi, F. Asai, T. Ogawa, T. Inoue, and H. Koike The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties Br. J. Pharmacol. 129 2000 1439 1446
219. T. Suzuki, K. Namba, H. Tsuga, and H. Nakata Regulation of pharmacology by hetero-oligomerization between A1 adenosine receptor and P2Y2 receptor Biochem. Biophys. Res. Commun. 351 2006 559 565
220. S. Syberg, A. Brandao-Burch, J.J. Patel, M. Hajjawi, T.R. Arnett, P. Schwarz, and et al. Clopidogrel (Plavix), a P2Y12 receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo J. Bone Min. Res. 27 2012 2373 2386
221. J. Takasaki, M. Kamohara, T. Saito, M. Matsumoto, S. Matsumoto, T. Ohishi, and et al. Molecular cloning of the platelet P2TAC ADP receptor: pharmacological comparison with another ADP receptor, the P2Y1 receptor Mol. Pharmacol. 60 2001 432 439
222. C. Tan, U. Voss, S. Svensson, D. Erlinge, and B. Olde High glucose and free fatty acids induce beta cell apoptosis via autocrine effects of ADP acting on the P2Y(13) receptor Purinergic Signal 9 2013 67 79
223. J. Tauber, W.F. Davitt, J.E. Bokosky, K.K. Nichols, B.R. Yerxa, A.E. Schaberg, and et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye Cornea 23 2004 784 792
224. Y. Tokuyama, M. Hara, E.M. Jones, Z. Fan, and G.I. Bell Cloning of rat and mouse P2Y purinoceptors Biochem. Biophys. Res. Commun. 211 1995 211 218
225. B. Torres, A.C. Zambon, and P.A. Insel P2Y11 receptors activate adenylyl cyclase and contribute to nucleotide-promoted cAMP formation in MDCK-D1 cells. A mechanism for nucleotide-mediated autocrine-paracrine regulation J. Biol. Chem. 277 2002 7761 7765
226. H. Tozaki-Saitoh, M. Tsuda, H. Miyata, K. Ueda, S. Kohsaka, and K. Inoue P2Y12 receptors in spinal microglia are required for neuropathic pain after peripheral nerve injury J. Neurosci. 28 2008 4949 4956
227. H. Ullmann, S. Meis, D. Hongwiset, C. Marzian, M. Wiese, P. Nickel, and et al. Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency J. Med. Chem. 48 2005 7040 7048
228. I. von Kügelgen Pharmacological profiles of cloned mammalian P2Y-receptor subtypes Pharmacol. Ther. 110 2006 415 432
229. I. von Kügelgen, and T.K. Harden Molecular pharmacology, physiology, and structure of the P2Y receptors Adv. Pharmacol. 61 2011 373 415
230. I. von Kügelgen, and A. Wetter Molecular pharmacology of P2Y-receptors Schmiedeb. Arch. Pharmacol. 362 2000 310 323
231. U. Voss, M.F. Turesson, B. Robaye, J.M. Boeynaems, B. Olde, D. Erlinge, and E. Ekblad The enteric nervous system of P2Y13 receptor null mice is resistant against high-fat-diet- and palmitic-acid-induced neuronal loss Purinergic Signal 10 2014 455 464
232. G.L. Waldo, and T.K. Harden Agonist binding and Gq-stimulating activities of the purified human P2Y1 receptor Mol. Pharmacol. 65 2004 426 436
233. G.L. Waldo, J. Corbitt, J.L. Boyer, G. Ravi, H.S. Kim, X.D. Ji, and et al. Quantitation of the P2Y1 receptor with a high affinity radiolabeled antagonist Mol. Pharmacol. 62 2002 1249 1257
234. N. Wang, B. Robaye, F. Gossiel, J.M. Boeynaems, and A. Gartland The P2Y13 receptor regulates phosphate metabolism and FGF-23 secretion with effects on skeletal development FASEB J. 28 2014 2249 2259
235. T.E. Webb, J. Simon, B.J. Krishek, A.N. Bateson, T.G. Smart, B.F. King, and et al. Cloning and functional expression of a brain G-protein-coupled ATP receptor FEBS Lett. 324 1993 219 225
236. T.E. Webb, D. Henderson, B.F. King, S. Wang, J. Simon, A.N. Bateson, and et al. A novel G protein-coupled P2 purinoceptor (P2Y3) activated preferentially by nucleoside diphosphates Mol. Pharmacol. 50 1996 258 265
237. C.M. Webster, M. Hokari, A. McManus, X.N. Tang, H. Ma, R. Kacimi, and M.A. Yenari Microglial P2Y12 deficiency/inhibition protects against brain ischemia PloS One 8 2013 e70927 10.1371/journal.pone.0070927
238. S. Weyler, Y. Baqi, P. Hillmann, M. Kaulich, A.M. Hunder, I.A. Müller, and et al. Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists Bioorg Med. Chem. Lett. 18 2008 223 227
239. P.J. White, T.E. Webb, and M.R. Boarder Characterization of a Ca2+ response to both UTP and ATP at human P2Y11 receptors: evidence for agonist-specific signaling Mol. Pharmacol. 63 2003 1356 1363
240. S.S. Wildman, R.J. Unwin, and B.F. King Extended pharmacological profiles of rat P2Y2 and rat P2Y4 receptors and their sensitivity to extracellular H+ and Zn2+ ions Br. J. Pharmacol. 140 2003 1177 1186
241. F. Wilkin, X. Duhant, C. Bruyns, N. Suarez-Huerta, J.M. Boeynaems, and B. Robaye The P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells J. Immunol. 166 2001 7172 7177
242. M. Yamane, Y. Ogawa, M. Fukui, M. Kamoi, Y. Saijo-Ban, S. Yaguchi, and et al. Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye Optom. Vis. Sci. 92 2015 S25 S32
243. S. Yelovitch, J. Camden, G.A. Weisman, and B. Fischer Boranophosphate isoster controls P2Y-receptor subtype selectivity and metabolic stability of dinucleoside polyphosphate analogues J. Med. Chem. 55 2012 437 448
244. K. Yoshioka, O. Saitoh, and H. Nakata Heteromeric association creates a P2Y-like adenosine receptor Proc. Natl. Acad. Sci. U. S. A. 98 2001 7617 7622
245. K. Yoshioka, O. Saitoh, and H. Nakata Agonist-promoted heteromeric oligomerization between adenosine A1 and P2Y1 receptors in living cells FEBS Lett. 523 2002 147 151
246. A.C. Zambon, L.L. Brunton, K.E. Barrett, R.J. Hughes, B. Torres, and P.A. Insel Cloning, expression, signaling mechanisms, and membrane targeting of P2Y11 receptors in Madin Darby canine kidney cells Mol. Pharmacol. 60 2001 26 35
247. M. Zerr, B. Hechler, M. Freund, S. Magnenat, I. Lanois, J.P. Cazenave, and et al. Major contribution of the P2Y1 receptor in purinergic regulation of TNFa-induced vascular inflammation Circulation 123 2011 2404 2413
248. F.L. Zhang, L. Luo, E. Gustafson, J. Lachowicz, M. Smith, X. Qiao, and et al. ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999 J. Biol. Chem. 276 2001 8608 8615
249. F.L. Zhang, L. Luo, E. Gustafson, K. Palmer, X. Qiao, X. Fan, and et al. P2Y13: identification and characterization of a novel Galphai-coupled ADP receptor from human and mouse J. Pharmacol. Exp. Ther. 301 2002 705 713
250. Y. Zhang, I.L. Pop, N.G. Carlson, and B.K. Kishore Genetic deletion of the P2Y2 receptor offers significant resistance to development of lithium-induced polyuria accompanied by alterations in PGE2 signaling Am. J. Physiol. Ren. Physiol. 302 2012 F70 F77
251. Y. Zhang, L. Li, D.E. Kohan, C.M. Ecelbarger, and B.K. Kishore Attenuation of lithium-induced natriuresis and kaliuresis in P2Y2 receptor knockout mice Am. J. Physiol. Ren. Physiol. 305 2013 F407 F416
252. K. Zhang, J. Zhang, Z.G. Gao, D. Zhang, L. Zhu, G.W. Han, and et al. Structure of the human P2Y12 receptor in complex with an antithrombotic drug Nature 509 2014 115 118
253. J. Zhang, K. Zhang, Z.G. Gao, S. Paoletta, D. Zhang, G.W. Han, and et al. Agonist-bound structure of the human P2Y12 receptor Nature 509 2014 119 122
254. Y. Zhang, J. Peti-Peterdi, C.E. Müller, N.G. Carlson, Y. Baqi, D.L. Strasburg, and et al. P2Y12 receptor localizes in the renal collecting duct and its blockade augments arginine vasopressin action and alleviates nephrogenic diabetes insipidus J. Am. Soc. Nephrol. 2015 10.1681/ASN.2014010118 in press
255. D. Zhang, Z.G. Gao, K. Zhang, E. Kiselev, S. Crane, J. Wang, and et al. Two disparate ligand-binding sites in the human P2Y1 receptor Nature 520 2015 317 321